Kamada Stock News

Kamada Ltd (NASDAQ: KMDA ) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics . Kamada will pay Saol a $95 million upfront payment and an additional $50 million in sales milestones during 2022-2034. The combined annual global revenue of the acquired portfolio in 2021 is expected to be $40 million - $45 Full story available on Benzinga.com

Kamada Ltd. (KMDA) CEO Amir London on Q3 2021 Results - Earnings Call Transcript

REHOVOT, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2021.

Kamada Ltd (NASDAQ: KMDA) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics. Kamada will pay Saol a $95 million upfront payment and an additional

Kamada (KMDA) delivered earnings and revenue surprises of -166.67% and 8.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kamada (NASDAQ:KMDA) reported its Q3 earnings results on Monday, November 22, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

On November 22, Kamada will report latest earnings. Analysts on Wall Street predict Kamada will release earnings per share of $0.027. Track Kamada stock price in real-time on Markets Insider here. On November 22, Kamada

Wall Street brokerages expect Kamada Ltd. (NASDAQ:KMDA) to report earnings of $0.03 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kamadas earnings, with the lowest EPS estimate coming in at $0.02 and the highest estimate coming in at $0.03. Kamada posted earnings of $0.16 per share []

BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021

Kamada Limited (KMDA) CEO Amir London on Q2 2021 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

REHOVOT, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FORT LEE, N.J. and REHOVOT, Israel, June 2, 2021 /PRNewswire/ -- Kedrion Biopharma and Kamada Ltd.